Literature DB >> 33130384

Osteosarcoma: A comprehensive review of management and treatment strategies.

Farzaneh Jafari1, Saeed Javdansirat2, Sarvin Sanaie3, Amirreza Naseri4, Ali Shamekh4, Davood Rostamzadeh5, Sanam Dolati6.   

Abstract

Osteosarcoma, a bone cancer usually seen in children and young adults, is generally a high-grade malignancy presented by extreme metastases to the lungs. Osteosarcoma has a tendency for appearing in bones with rapid growth rate. The etiology of osteosarcoma is multifaceted and poorly understood. A molecular consideration of this disease will lead to a directed tumor treatment. The present treatment for osteosarcoma comprises of an arrangement of systemic chemotherapy and wide surgical resection. Survival rate is increased by the progress of destructive systemic chemotherapies. So, the development of new treatment approaches for metastatic osteosarcoma is essential. Immunomodulation has been used in clinical settings. Through targeting surface antigens expressed on tumor cells, particular antibodies and exploitation of cellular immunotherapy against sarcomas have been confirmed to be effective as cancer therapeutics. In this article, we have reviewed epidemiology, etiology, pathogenesis, diagnosis, and treatment of osteosarcoma and we have focused on different methods of immunotherapy including vaccines, cell-based immunotherapy, cytokines, and monoclonal antibodies.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody; Cytokines; Immunotherapy; Metastasis; Osteosarcoma

Year:  2020        PMID: 33130384     DOI: 10.1016/j.anndiagpath.2020.151654

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  33 in total

1.  Transcription factor c-Myb: novel prognostic factor in osteosarcoma.

Authors:  Kamila Říhová; Monika Dúcka; Iva Staniczková Zambo; Ladislava Vymětalová; Martin Šrámek; Filip Trčka; Jan Verner; Stanislav Drápela; Radek Fedr; Tereza Suchánková; Barbora Pavlatovská; Eva Ondroušková; Irena Kubelková; Danica Zapletalová; Štěpán Tuček; Peter Múdry; Dagmar Adámková Krákorová; Lucia Knopfová; Jan Šmarda; Karel Souček; Lubor Borsig; Petr Beneš
Journal:  Clin Exp Metastasis       Date:  2022-01-07       Impact factor: 5.150

2.  [MiR-671-5p negatively regulates SMAD3 to inhibit migration and invasion of osteosarcoma cells].

Authors:  Y Hu; D Liang; X Chen; L Chen; J Bai; H Li; C Yin; W Zhong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-10-20

3.  Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6-Cyclin D-Rb pathway.

Authors:  Deli Wang; Haiqin Bao
Journal:  Cancer Chemother Pharmacol       Date:  2021-10-16       Impact factor: 3.333

4.  Slow release curcumin-containing soy protein nanoparticles as anticancer agents for osteosarcoma: synthesis and characterization.

Authors:  Hadi Zare-Zardini; Hossein Soltaninejad; Adel Ghorani-Azam; Reza Nafisi-Moghadam; Navid Haddadzadegan; Mojtaba Ansari; Seyed Houssein Saeed-Banadaki; Mohammad Reza Sobhan; Sima Mozafari; Mahlagha Zahedi
Journal:  Prog Biomater       Date:  2022-07-25

5.  [RHPN2 is highly expressed in osteosarcoma cells to promote cell proliferation and migration and inhibit apoptosis].

Authors:  Z Liu; F Fang; J Li; G Zhao; Q Zang; F Zhang; J Die
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-09-20

6.  Dihydrotanshinone I Enhances Cell Adhesion and Inhibits Cell Migration in Osteosarcoma U-2 OS Cells through CD44 and Chemokine Signaling.

Authors:  Lanyan Fan; Chen Peng; Xiaoping Zhu; Yawen Liang; Tianyi Xu; Peng Xu; Shihua Wu
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

7.  The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.

Authors:  Lijiang He; Hainan Yang; Jingshan Huang
Journal:  BMC Cancer       Date:  2021-05-21       Impact factor: 4.430

8.  Clinical therapeutic effects of combined methotrexate and other chemotherapeutic agents in treating children and young patients with osteosarcoma: A protocol for systematic review and meta-analysis.

Authors:  Cheng Peng; Zhinan Ren; Jian Zhu; Panke Zhang; Shuyan Cao; Yingjie Hao
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

Review 9.  Role of MicroRNAs in Human Osteosarcoma: Future Perspectives.

Authors:  Lola Llobat; Olivia Gourbault
Journal:  Biomedicines       Date:  2021-04-23

10.  N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.

Authors:  Kun Yang; Fengyan Wang; Ke Li; Guoxuan Peng; Hua Yang; Hong Xu; Yang Xiang; Hong Sun
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.